AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04213690 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study NCT00679965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690, 2.5%
Description: Once daily application for 90 days and 3 x weekly for 90 days
Study NCT00679965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690, 5%
Description: Once daily application for 90 days and 3 x weekly for 90 days
Study NCT00679965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690, 7.5%
Description: Once daily application for 90 days and 3 x weekly for 90 days
Study NCT00679965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AN2690 Solution Vehicle
Description: Once daily application for 90 days and 3x weekly for 90 days
Study NCT03255421 — intervention group
Intervention type: OTHER
Intervention: Pressure measurement
Description: Observational study No intervention, only fragmenting the emptying of the bladder
Study NCT00813293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Study NCT00813293 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: radiofrequency ablation
Study NCT00813293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Study NCT01682083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Each capsule contained 50 mg or 75 mg of free base (present as the mesylate salt)
Study NCT01682083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Each tablet contained 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
Study NCT01682083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The placebo capsules and tablets contained the same inactive ingredients and film coatings as the dabrafenib and trametinib study treatment
Study NCT02544594 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extra-Corporal Life Support (ECLS)
Description: Extra-Corporal Life Support (ECLS) (from Sorin)
Study NCT00860405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion), Human serum albumin (HSA 50g/L)
Description: Study medication will be given as part of the priming of the ECC and for plasma volume replacement after start of ECC up to the maximum dosage of 50 mL/kg body weight/day.
Study NCT00860405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human serum albumin (HSA 50g/L)
Description: Human serum albumin (HSA 50g/L)
Study NCT01728922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 5000IU vitamin D
Description: Vigantol Oil
Study NCT01728922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 10000IU vitamin D
Description: Vigantol Oil
Study NCT01728922 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Oil
Study NCT04406441 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Reported Outcome Well Child Visit
Description: Parents will complete the Family Nutrition and Physical Activity risk assessment (Patient Reported Outcome) prior to scheduled well child visit. Parent reported data is integrated into the child's electronic health record to inform the child's primary care provider and the provision of preventive counseling. The primary care provider documents preventive care provided.
Study NCT04473417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2811
Description: single dose administration after 10hr fasting
Study NCT04406441 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Reported Outcome Well Child Visit + Food Care
Description: Adapted Parent Training Program will be delivered via telehealth (video or telephone) to parents by trained Wellness Coaches as 6 individual sessions, distributed throughout a 26-week intervention period. Cooking Matters grocery store tours will be delivered (in-person or virtual) to parents by trained grocery store nutritionists during the 26-week intervention period.
Study NCT03559023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Only
Description: The anesthesia team will use ultrasound to scan on subject's upper back (thoracic spine) to identify a place to begin the epidural procedure. A pen will be used to place markings on subject's back.
Study NCT03559023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manometry Only
Description: The anesthesia team will use an extra piece of tubing to confirm the epidural space one the epidural space is established.
Study NCT03559023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Plus Manometry
Description: The anesthesia team will use both ultrasound and manometry to assist with epidural placement.
Study NCT03559023 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Usual Care/Management
Description: The epidural will be placed using the usual technique utilized by the anesthesiology department. The the usual care/management group will receive a sham (fake) ultrasound exam of subject's upper back with fake pen markings placed on subject's back. The ultrasound machine will not be turned on.
Study NCT01563965 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate plus hydrolyzed protein beverage
Description: The study group received 400 ml (evening drink) or 200 ml (3h prior to operation drink) of a solution containing 11% de protein (pea hydrolized proptein), 89% de carbohydrates (maltodextrin 79% and saccharose 21%) e 0% of lipids (Providextra, Fresenius Kabi, São Paulo, Brasil). All the patients fasted for solids at least 6 hours from the operation
Study NCT01563965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative fasting of 8h
Description: Conventional protocol of 8h fasting before an operation
Study NCT02987491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will perform 2 metabolic study days of either resting or acute bout of cycling exercise in a randomized cross-over design.
Study NCT01895205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000
Study NCT01895205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Study NCT03195374 — intervention group
Intervention type: OTHER
Intervention: Prescription Opioid Misus Index
Description: Opioid misuse will be assessed by the Prescription Opioid Misuse Index (POMI) scale. A score ≥ 2 is considered positive and will define a misuse behavior.
Study NCT02379247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL-719 (alpelisib)
Description: Oral PI3K inhibitor
Study NCT02379247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV taxane
Study NCT03037372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART, Atorvastatin
Description: ART, Atorvastatin
Study NCT03037372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART, Rosuvastatin
Description: ART, Rosuvastatin
Study NCT03037372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART, No statin
Description: ART, No statin
Study NCT04473417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2811
Description: single dose administration after high fat and calorie fed diet
Study NCT02492438 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPV23 vaccination or PCV13 vaccination
Study NCT02492438 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV23 vaccination or PCV13 vaccination
Study NCT00744445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-HuEPO
Description: r-HuEPO 50 U/kg s.c. three times per week. The dose is rounded to the nearest 2000 unites.
Study NCT02734069 — intervention group
Intervention type: DRUG
Intervention: Carboplatin
Description: Patients will receive carboplatin according to the carboplatin area under the curve dose calculation for 2 cycles to evaluate toxicity.
Study NCT04484532 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: Given IM
Study NCT03037372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Healthy-HIV-negative
Description: Age-matched, Healthy HIV-negative
Study NCT01190163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Study NCT01190163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study NCT02351154 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cellvizio Viewer software
Description: permets to perform analysis of diameters in micrometers
Study NCT02598479 — intervention group
Intervention type: OTHER
Intervention: IPTLD and nutrition therapy
Description: The measurement of Quality of Life in patients who choose to use Insulin Potentiation Low Dose Therapy and Nutritional Therapy in the treatment of cancer
Study NCT03206866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum regucalcin antibody
Description: serum regucalcin antibody
Study NCT03971825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92252
Description: CC-92252
Study NCT03971825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT02724800 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBTI
Description: 28 Veterans with chronic insomnia will be randomized to CBTI. The intervention will be delivered in 5 face-to-face session within an 8 week time period. The intervention will be delivered at the VA Pittsburgh Healthcare System. Treatment visits will last approximately 45 minutes.
Study NCT02724800 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BBTI
Description: 28 Veterans with chronic insomnia will be randomized to BBTI. The intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3 (option for telephone), and telephone appointments on Weeks 2 and 4. Interventions will be delivered at the VA Pittsburgh Healthcare System. The duration of the first treatment visit is approximately 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (\<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
Study NCT03095846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooling
Description: Individualized cooling protocol
Study NCT00952406 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: This is a study to develop a survey for sexual health in women with pelvic floor dysfunction
Study NCT03139019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Process incentives
Description: Participants will receive cash based incentives for achieving process based measures (class attendance).
Study NCT03139019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outcome incentives
Description: Participants will receive cash based incentives for outcome based measures (weight loss).
Study NCT03139019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Process and Outcome incentives
Description: Participants will receive cash based incentives for both achieving process based measures (class attendance) and outcome based measures (weight loss).
Study NCT00389064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: Quetiapine XR 50 mg tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily, in the evening for a 9-week treatment period.
Study NCT00389064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets orally administered in flexible doses of 50 to 300 mg once daily, in the evening for a 9-week treatment period.
Study NCT00376922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: music therapy
Description: music played for patient during bone marrow biopsy collection
Study NCT02869425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arbaclofen ER Tablets
Description: arbaclofen ER tablets, 10 mg, 15 mg, or 20 mg
Study NCT02869425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for arbaclofen ER tablets
Description: matching placebo tablets to arbaclofen ER tablets 10 mg, 15 mg or 20 mg
Study NCT01631422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4602522
Description: Single radiolabeled dose
Study NCT00907998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL180
Study NCT00907998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00784823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib 1 mg/m2
Description: * Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~* Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~* Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen
Study NCT00784823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m2
Description: * Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~* Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~* Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen
Study NCT00784823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.6 mg/m2
Description: * Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~* Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~* Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen
Study NCT05182346 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: * Acupressure of acupoints is manipulation of classic acupoints by pressure.~* Ischemic compression release is applying pressure to the myofascial trigger points until release of these points.
Study NCT00784823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: * Melphalan is administered by rapid intravenous infusion via a central or peripheral vein over one hour~* Melphalan will be dissolved with 10 ml of diluent to a concentration of 5 mg/mL which is then immediately diluted in 0.9% normal saline to a concentration NOT exceeding 0.45 mg/mL prior to administration~* The final dilution of melphalan is physically and chemically stable for 60 minutes and therefore will be administered within that time period~* Melphalan will be given as a single dose (not split over 2 or more days)~* Dosing will be based body surface area calculated using actual body weight
Study NCT03855332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: See above
Study NCT03855332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: See above
Study NCT03855332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Overencapsulated placebo
Study NCT00863746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib 400 mg twice daily (BID)
Study NCT00863746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - 2 tablets twice daily (BID)
Study NCT02096510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-Cortef
Description: administration by pump for minimum 2 weeks
Study NCT02421341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: During study visits 2 and 3 you will receive an intrathecal (fluid filled space surrounding the spinal cord) injection of either fentanyl or placebo (saline). Fentanyl is an opiate (narcotic) drug and a common medication, however the way fentanyl is being used in this study is considered investigational.
Study NCT02421341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheters
Description: A catheter (small plastic tube placed in a blood vessel) will be placed in an artery in your arm and a second catheter will be placed in a vein in your leg. Local anesthetic will be used to minimize discomfort. These catheters will allow us to measure blood pressure, leg blood flow and draw blood.
Study NCT02421341 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Catheters
Description: A catheter (small plastic tube placed in a blood vessel) will be placed in an artery in your arm and a second catheter will be placed in a vein in your leg. Local anesthetic will be used to minimize discomfort. These catheters will allow us to measure blood pressure, leg blood flow and draw blood.
Study NCT02421341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: You will be asked to exercise, ride a stationary bike, at maximal exertion.
Study NCT02421341 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: You will be asked to exercise, ride a stationary bike, at maximal exertion.
Study NCT02421341 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DEXA
Description: During study visit one you will have a DEXA scan. This procedure requires you to lie on a table while a small x-ray tube passes under your body.
Study NCT02421341 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: DEXA
Description: During study visit one you will have a DEXA scan. This procedure requires you to lie on a table while a small x-ray tube passes under your body.
Study NCT04478344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided hydrodissection of superior cluneal nerve
Description: Intervention procedure: hydrodissection to the superior cluneal nerve entrapment; Device for guidance of injection: high-resolution ultrasound ; Drug for injection: a mixture of 1 mL of 50% dextrose, 4 mL of 1% lidocaine, and 5 mL of 0.9% normal saline
Study NCT01764139 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling
Study NCT01155128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise aerobic
Description: The intervention will consist of physical exercise sessions for approximately 60 minutes and two weekly sessions. The classes will consist of an initial part to exercises heating joint flexibility and lasting 10 minutes, a major part consists of aerobic exercise, lasting 20-30 minutes, and a piece of muscular endurance with exercises upper and lower limbs and abdomen, lasting 10-20 minutes. The intensity will be controlled through the Subjective Perception Scale Borg
Study NCT01155128 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: exercise aerobic
Description: The intervention will consist of physical exercise sessions for approximately 60 minutes and two weekly sessions. The classes will consist of an initial part to exercises heating joint flexibility and lasting 10 minutes, a major part consists of aerobic exercise, lasting 20-30 minutes, and a piece of muscular endurance with exercises upper and lower limbs and abdomen, lasting 10-20 minutes. The intensity will be controlled through the Subjective Perception Scale Borg
Study NCT00864695 — intervention group
Intervention type: OTHER
Intervention: Supportive care
Description: protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject's health or function. In general, supportive care interventions are not intended to cure a disease.
Study NCT03562988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin C gummy
Description: vitamin C
Study NCT03562988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin C tablet
Description: vitamin C
Study NCT02421341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Tests
Description: During study visit one you will be asked to perform 5 different breathing tests to help us better understand your lung function.
Study NCT02421341 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary Function Tests
Description: During study visit one you will be asked to perform 5 different breathing tests to help us better understand your lung function.
Study NCT02421341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: You will have approximately 350 mls (1.25 cups) of blood drawn during the duration of this study.
Study NCT02421341 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood Draw
Description: You will have approximately 350 mls (1.25 cups) of blood drawn during the duration of this study.
Study NCT02421341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemosensitivity Test
Description: Using a bag you breath in and out your own air.
Study NCT02421341 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chemosensitivity Test
Description: Using a bag you breath in and out your own air.
Study NCT02421341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01027533 — intervention group
Intervention type: OTHER
Intervention: Implantation of a multifocal Intraocular lens
Description: Bilateral implantation of a multifocal IOl
Study NCT00501982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poractant alfa (Curosurf®)